CNS Pharmaceuticals names Rami Levin as new president and CEO

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced that John Climaco has stepped down as chief executive officer and Rami Levin has been appointed as president and chief executive officer, effective January 1, 2026.

Levin brings nearly 30 years of experience in oncology, neurology, rare diseases, endocrinology, and cell and gene therapy. He previously served as president and CEO of Saniona and CEO of ImStem Biotechnology. Levin also held senior roles at Sobi, Merck Serono, and Schering AG, where he worked on brands including Rebif, Betaseron, Kuvan, Orfadin, and Gamifant.

At Sobi, Levin led the transformation of the North American business, growing revenues from approximately $46 million to more than $500 million while expanding the organization to over 300 employees.

"We are grateful to John and his dedicated service to CNS Pharmaceuticals and wish him all the best in his next endeavors," said Faith Charles, chair of the board of directors. "Looking ahead, Rami is a seasoned biotech leader with a rare combination of scientific depth, commercial execution, and capital markets expertise."

Levin holds an MBA from the Recanati Business School at Tel Aviv University and a bachelor's degree in biology from Tel Aviv University. He has completed executive training programs at INSEAD, IMD, and Kellogg School of Management at Northwestern University.

CNS Pharmaceuticals is a clinical-stage company developing treatments for primary and metastatic cancers of the brain and central nervous system. The company's drug candidate TPI 287 has been tested in over 350 patients for various conditions including recurrent glioblastoma and breast cancer metastatic to the brain.

You May Also Be Interested In

• Anthropic Signs $35b Cloud Deal With Lambda In Texas: WSJ
• ONEOK to buy Brazos Midstream Permian assets for $4.43B
• TryHard Holdings regains Nasdaq compliance after reverse stock split